Target type: cellularcomponent
Protein complex that carries out the reaction: ATP + H2O + K+(out) = ADP + phosphate + K+(in). It is a high affinity potassium uptake system. The E. coli complex consists of 4 proteins: KdpA is the potassium ion translocase, KdpB is the ATPase, and KdpC and KdpF seem to be involved in assembly and stabilization of the complex. [PMID:10608856, PMID:9858692]
The potassium ion-transporting ATPase complex, also known as the Na+/K+ ATPase or sodium-potassium pump, is a transmembrane protein complex crucial for maintaining cellular ion gradients and electrochemical potential. It is embedded in the plasma membrane, specifically the lipid bilayer, and its primary function is to transport sodium ions out of the cell and potassium ions into the cell, against their concentration gradients. This active transport process requires energy, which is supplied by the hydrolysis of ATP.
The complex is composed of two subunits: the α subunit and the β subunit. The α subunit is responsible for the catalytic activity and contains the binding sites for sodium, potassium, and ATP. It has ten transmembrane domains and is responsible for the actual ion transport. The β subunit is a glycoprotein that aids in the assembly and stability of the α subunit and may also regulate its activity. It has only one transmembrane domain and is located on the outer surface of the membrane.
The α subunit has two main conformations: E1 and E2. In the E1 conformation, the binding sites for sodium ions are accessible from the intracellular side, while in the E2 conformation, the binding sites for potassium ions are accessible from the extracellular side.
The overall process of ion transport can be summarized in the following steps:
1. Three sodium ions bind to the α subunit from the intracellular side, in the E1 conformation.
2. ATP binds to the α subunit and is hydrolyzed, releasing energy.
3. The conformational change to E2 occurs, exposing the sodium binding sites to the extracellular side and the potassium binding sites to the intracellular side.
4. Two potassium ions bind to the α subunit from the extracellular side.
5. The conformational change back to E1 occurs, exposing the potassium binding sites to the intracellular side and releasing the sodium ions to the extracellular side.
6. The potassium ions are released into the intracellular side, and the cycle repeats.
This process plays a vital role in maintaining the cell's membrane potential, which is essential for various cellular functions such as nerve impulse transmission, muscle contraction, and nutrient uptake.
The potassium ion-transporting ATPase complex is a highly regulated protein complex. Its activity can be modulated by various factors, including phosphorylation, changes in membrane potential, and interactions with other proteins. Dysfunction of this complex can lead to various diseases, including heart failure, hypertension, and neurological disorders.'
"
Protein | Definition | Taxonomy |
---|---|---|
ATP-sensitive inward rectifier potassium channel 8 | An ATP-sensitive inward rectifier potassium channel 8 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q15842] | Homo sapiens (human) |
ATP-binding cassette sub-family C member 8 | An ATP-binding cassette sub-family C member 8 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q09428] | Homo sapiens (human) |
ATP-binding cassette sub-family C member 9 | An ATP-binding cassette sub-family C member 9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60706] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
diazoxide | diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. | benzothiadiazine; organochlorine compound; sulfone | antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent |
glyburide | glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group. Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide | monochlorobenzenes; N-sulfonylurea | anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent |
pinacidil | Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed) | pyridines | |
propafenone | propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias. Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. | aromatic ketone; secondary alcohol; secondary amino compound | anti-arrhythmia drug |
troglitazone | Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity. | chromanes; thiazolidinone | anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent |
n-cyano-n'-(1,1-dimethylpropyl)-n''-(3-pyridinyl)guanidine | N-cyano-N'-(1,1-dimethylpropyl)-N''-(3-pyridinyl)guanidine: potassium channel opener | pyridines | |
repaglinide | piperidines | ||
cromakalim | Cromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352) | ||
rosiglitazone | aminopyridine; thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug | |
mk 767 | 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source | ||
zeneca zd 6169 | Zeneca ZD 6169: an ATP-sensitive potassium channel opener; structure given in first source | ||
cromakalim | 1-benzopyran | ||
clamikalant | clamikalant: inhibits ATP-sensitive potassium channel; structure in first source | ||
zm226600 | ZM226600: an ATP-sensitive potassium channel opener; structure in first source | anilide | |
way 133537 | |||
ly 465608 | LY 465608: a nonthiazolidinedione agonist of both PPAR-alpha and PPAR-gamma of Ligand Pharm. and Eli Lilly | ||
bm 131246 | |||
nn 414 | NN 414: a hypoglycemic agent with insulin release modulating and potassium channel activating activities; structure in first source | ||
7-chloro-3-isopropylamino-4h-1,2,4-benzothiadiazine 1,1-dioxide | 7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide: activates ATP-sensitive potassium channels; structure in first source |